New Pharmaceuticals market report from Datamonitor: "MAP Pharmaceuticals: PharmaVitae Report"
Boston, MA -- (SBWIRE) -- 07/26/2012 -- This analysis evaluates the company's strategy and key strengths, weaknesses, opportunities and threats, and provides an overview of the company's historical and forecast financial performance. The report also gives an in-depth analysis of the company's key prescription pharmaceutical product, and provides a forecast sales performance for this drug.
- Gain insight into MAP Pharmaceuticals' strategic outlook
- Analyze company sales forecasts by product
MAP's most advanced product candidate is Levadex (dihydroergotamine), an orally inhaled migraine therapy, which represents the main driver for the company. MAP received a Complete Response Letter from the FDA on March 26, 2012
View Full Report Details and Table of Contents
Reasons to Get this Report
- Benchmark MAP Pharmaceuticals' performance against key rivals in the prescription pharmaceutical sector
- Assess how successful MAP Pharmaceuticals will be in obtaining marketing approval for its first product
About Fast Market Research
Fast Market Research is an online aggregator and distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff will help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.
Browse all Pharmaceuticals research reports at Fast Market Research
You may also be interested in these related reports:
- MAP Pharmaceuticals, Inc. - Product Pipeline Review - H2 2011
- Ariad Pharmaceuticals: PharmaVitae Report
- MAP Pharmaceuticals, Inc. (MAPP) - Financial and Strategic SWOT Analysis Review
- Regeneron Pharmaceuticals, Inc.: PharmaVitae Report
- Amylin Pharmaceuticals, Inc.: PharmaVitae Report
- King Pharmaceuticals, Inc - Strategy, SWOT, and Corporate Finance Report
- Endo Pharmaceuticals Holdings Inc. - Strategy, SWOT, and Corporate Finance Report
- Cubist Pharmaceuticals, Inc. - Strategy, SWOT, and Corporate Finance Report
- Watson Pharmaceuticals, Inc. - Strategy, SWOT, and Corporate Finance Report
- Progenics Pharmaceuticals, Inc. - Strategy, SWOT, and Corporate Finance Report